+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Phenylketonuria Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon

    Report

  • 117 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5529444
UP TO OFF until Sep 30th 2022

The phenylketonuria treatment market is expected to register a CAGR of around 11 % over the forecast period. The growing burden of phenylketonuria disease and the novel treatments emerging related to phenylketonuria is expected to boost the phenylketonuria treatment market growth. According to the National PKU Alliance, the chances of the gene carrier is around one in fifty people, and the chances of two carriers mating are expected to be around 25%. The degree of affecting the disease is majorly based upon ethnicity and geographical region. According to the same source, in Ireland, around 1 out of 4,500 population is diagnosed with it. Similarly, in Asia, 1 out of 20,000 is diagnosed with it, while in Turkey the incidence is high, i.e., 1 in 4,000.



Key Market Trends


Kuvan Phenylketonuria Treatment Segment is Expected to Hold a Major Market Share in the Phenylketonuria Treatment Market


Kuvan is the only drug present currently for the efficient treatment of phenylketonuria, which is being manufactured by BioMarin Pharmaceuticals. It adds more BH4 compound, helps in stimulating phenylalanine hydroxylase enzyme, which then breakdown the phenylalanine protein. In 2017, it lost its patent, and BioMarin Pharmaceuticals gave license to Par Pharmaceuticals to develop a generic version of Kuvan.



North America is Expected to Hold a Significant Share in the Market during the Forecast Period


North America expected to hold a major market share in the global phenylketonuria treatment market due to a higher incidence rate of phenylketonuria and the development in treatment type. For instance, Homology Medicines Inc., a US-based genetic company, is developing a gene therapy, HMI-102, for phenylketonuria. Currently, its IND (Investigational New Drug) application has been approved by the USFDA (Food & Drug Administration), and it is undergoing the first phase of clinical trials to test safety and efficacy. According to the National Organization for Rare Disorders, there have been approximately 13,500 to 19,000 newborns diagnosed with phenylketonuria disease in the United States. According to the National Centre for Biotechnology Information published study “Phenylketonuria”, the disease is mostly found in Native Americans, and the incidence rate is around 1 in 15,000 people.



Competitive Landscape


The phenylketonuria treatment market is consolidated and consists of a few major players. Some of the companies currently dominating the market are BioMarin Pharmaceuticals Inc., Censa Pharmaceutical, Synlogic Inc., Erytech Pharma SA, Codexis Inc., SOM Innovation Biotech SL, Homology Medicines Inc., and Ultragenyx (Dimension Therapeutics).



Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence Rate of Phenylketonuria
4.2.2 Increasing Research and Development Activities in relation to Phenylketonuria Treatment
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Kuvan
5.1.2 Playnziq
5.1.3 Other Drugs
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Rest of the World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 BioMarin Pharmaceuticals Inc.
6.1.2 Censa Pharmaceuticals
6.1.3 Codexis Inc.
6.1.4 Erytech Pharma SA
6.1.5 Homology Medicines Inc.
6.1.6 Synlogic Inc.
6.1.7 SOM Innovation Biotech SL
6.1.8 Ultragenyx (Dimension Therapeutics)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Methodology

Loading
LOADING...